Targeting tumor and extracellular LPA could help deny tumors their inflammatory habitat and improve the efficacy of radiotherapy, chemotherapy, and possibly immunotherapies.
It is not always clear whether patients who discontinue anti-PD-1 and -CTLA-4 therapy should re-initiate treatment after adverse events are resolved.
The results of this study support previous findings that psychological distress is associated with an increased risk of mortality among patients with lung cancer.
c-MET, although rarer than T790M, may be a promising therapeutic target for patients who progress on EGFR TKI therapy.
Several ongoing clinical trials are also evaluating durvalumab as a single agent or in combination with other therapies, such as tremelimumab, and as a first-line therapy.
CONTINUUM suggests that maintenance therapy with lenalidomide is an effective way for prolonging progression-free survival without affecting potential subsequent lines of therapy.
Patients with underlying cardiovascular disease and/or baseline hypertension and coronary artery disease may be at a higher risk.
The future of chemotherapy-based options for patients with HER2-negative MBC is evolving, with emerging agents and combinations being studied in ongoing clinical trials.
Since the discovery of the notch pathway 25 years ago, several studies have found a link between different Notch receptors and specific forms of breast cancer, including triple-negative.
Liquid biopsy can be useful in cases where small bronchial biopsies contain a low number of tumor cells, and the repeatability of liquid biopsies can offer new approaches for monitoring patients treated with immunotherapy.
In the treatment of myeloma, researchers are using therapies engineered to target a protein on myeloma cells called B cell maturation antigen.
Researchers found that cells resistant to both BRAF inhibition and combination inhibition were sensitive to PAK inhibition, and further that PAK inhibition slowed cell-cycle progression.
About one-third of patients will experience disease recurrence after undergoing nephrectomy, and clinical trials exploring the use of adjuvant therapy in these patients produce conflicting results.
Ongoing trials, including those that combine immunotherapy with BRAF inhibitors or a triple combination of an anti-PD-1 antibody with BRAF and MEK inhibitors, may provide more options to patients.
While renal cell carcinoma treatment continue to improve, it's unclear whether pazopanib should be used in the adjuvant setting.
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Complete Resection of Metastatic Soft Tissue Sarcoma Associated With Improved Disease-specific Survival
- The Challenges of Immunotherapy Re-challenge in Metastatic Melanoma
- FDA Approves Fulvestrant/Abemaciclib Combination for Breast Cancer
- Beta-blockers May Prevent Stress-induced Lung Cancer Treatment Resistance
- Exercise May Mitigate Doxorubicin-related Cardiotoxicity
- FDA Expands Sunitinib Indication To Include Adjuvant Therapy for Renal Cell Carcinoma
- Ultrasonography May Detect Thyroid Cancer Growth Arrest, Negating Need for Treatment
- Does Education Level Predict PSA Screening and Prostate Cancer Survival?
- Unrelated HSCT, UCBT May Yield Similar Survival Outcomes in Acute Leukemia
- Minimal Residual Disease and Patient Genotype May Inform Relapse Risk Algorithms in ALL